MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
OptimizeRx Corporation Balance Sheet 2011-2026 | OPRX
Annual Balance Sheet OptimizeRx Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
20.6 M | -18 M | -84.4 M | -10.1 M | -18.3 M | -8.91 M | -5.12 M | -7.03 M | -8.21 M | -3.45 M | -1.12 M | -284 K | -959 K |
Long Term Debt |
34.2 M | 145 K | 237 K | 326 K | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
222 K | 89.9 K | 91 K | 123 K | 115 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 5.67 M | 2.36 M | - | - | - | - | - | - | - |
Total Current Liabilities |
17.9 M | 8.4 M | 9.37 M | 10 M | 6.11 M | 4.23 M | 3.54 M | 3.67 M | 3.37 M | 2.42 M | 2.28 M | 680 K | 1.3 M |
Total Liabilities |
56.8 M | 8.54 M | 9.61 M | 10.4 M | 11.8 M | 6.6 M | 3.54 M | 3.67 M | 3.37 M | 2.42 M | 1.97 M | 680 K | 1.3 M |
Deferred Revenue |
172 K | 164 K | 1.39 M | 286 K | 580 K | 611 K | 507 K | 387 K | 227 K | 120 K | 4.25 K | 49.3 K | 331 K |
Retained Earnings |
-64.3 M | -46.7 M | -35.3 M | -35.6 M | -33.4 M | -30.3 M | -30.4 M | -28.3 M | -26.7 M | -26.1 M | -24.6 M | -24.7 M | -24.4 M |
Total Assets |
183 M | 135 M | 141 M | 60.3 M | 56.6 M | 25.1 M | 9.76 M | 11.5 M | 12.3 M | 7.03 M | 4.01 M | 2.18 M | 2.89 M |
Cash and Cash Equivalents |
13.9 M | 18.2 M | 84.7 M | 10.5 M | 18.9 M | 8.91 M | 5.12 M | 7.03 M | 8.21 M | 3.45 M | 1.12 M | 284 K | 959 K |
Book Value |
127 M | 126 M | 131 M | 50 M | 44.9 M | 18.5 M | 6.22 M | 7.81 M | 8.94 M | 4.61 M | 2.04 M | 1.5 M | 1.59 M |
Total Shareholders Equity |
127 M | 126 M | 131 M | 50 M | 44.9 M | 18.5 M | 6.22 M | 7.81 M | 8.94 M | 4.61 M | 1.67 M | 1.4 M | 1.59 M |
All numbers in USD currency
Quarterly Balance Sheet OptimizeRx Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
24.8 M | 25.1 M | 29.2 M | 30.8 M | 33.3 M | 32.3 M | 32.4 M | 34.2 M | 5.8 K | 3.5 K | 123 K | 145 K | 167 K | 190 K | 213 K | 237 K | 261 K | 283 K | 305 K | 326 K | 326 K | 326 K | 326 K | 449 K | 449 K | 449 K | 449 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1 M | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 261 K | 283 K | 305 K | 326 K | 357 K | 326 K | 326 K | 5.67 M | 5.67 M | 5.67 M | 5.67 M | 2.36 M | 2.36 M | 2.36 M | 2.36 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
48.1 M | 50 M | 51.5 M | 54.2 M | 50.7 M | 51.9 M | 53.8 M | 56.8 M | 7.82 M | 5.51 M | 7.73 M | 8.54 M | 6.3 M | 6.63 M | 7.09 M | 9.61 M | 7.83 M | 6.95 M | 5.74 M | 10.4 M | 10.4 M | 10.4 M | 10.4 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 3.54 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.3 M | 739 K | 1.86 M | - |
Deferred Revenue |
395 K | 484 K | 511 K | 473 K | 786 K | 1.05 M | 904 K | 172 K | 188 K | 452 K | 735 K | 164 K | 673 K | 1.04 M | 1.29 M | 1.39 M | 348 K | 320 K | 448 K | 286 K | 286 K | 286 K | 286 K | 580 K | 580 K | 580 K | 580 K | 611 K | 611 K | 611 K | 611 K | 507 K | 507 K | 507 K | 507 K | 387 K | 387 K | 387 K | 387 K | 227 K | 227 K | 227 K | 227 K | 120 K | 120 K | 120 K | 120 K | 226 K | 4.25 K | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-84.3 M | -85 M | -86.6 M | -84.4 M | -84.3 M | -75.2 M | -71.2 M | -64.3 M | -60.1 M | -57.3 M | -53.1 M | -46.7 M | -46.4 M | -42.9 M | -39 M | -35.3 M | -35.9 M | -35.9 M | -36.3 M | -35.6 M | -35.6 M | -35.6 M | -35.6 M | -33.4 M | -33.4 M | -33.4 M | -33.4 M | -30.3 M | -30.3 M | -30.3 M | -30.3 M | -30.4 M | -30.4 M | -30.4 M | -30.4 M | -28.3 M | -28.3 M | -28.3 M | -28.3 M | -26.7 M | -26.7 M | -26.7 M | -26.7 M | -26.1 M | -26.1 M | -26.1 M | -26.1 M | -25.1 M | -24.6 M | -24.6 M | -24.6 M | -24.8 M | -24.7 M | -24.7 M | -24.7 M | -24.4 M | -24.4 M | -24.4 M | -24.4 M |
Total Assets |
170 M | 169 M | 168 M | 171 M | 165 M | 173 M | 176 M | 183 M | 124 M | 121 M | 132 M | 135 M | 136 M | 147 M | 138 M | 141 M | 135 M | 132 M | 128 M | 60.3 M | 60.3 M | 60.3 M | 60.3 M | 56.6 M | 56.6 M | 56.6 M | 56.6 M | 25.1 M | 25.1 M | 25.1 M | 25.1 M | 9.76 M | 9.76 M | 9.76 M | 9.76 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 7.03 M | 7.03 M | 7.03 M | 7.03 M | 3.95 M | 4.01 M | 4.01 M | 4.01 M | 2.18 M | 2.18 M | 2.18 M | 2.18 M | 2.89 M | 2.89 M | 2.89 M | 2.89 M |
Cash and Cash Equivalents |
19.5 M | 16.6 M | 16.6 M | 13.4 M | 16.1 M | 15 M | 15.2 M | 13.9 M | 9.92 M | 9.81 M | 16.4 M | 18.2 M | 41.3 M | 87.4 M | 89 M | 84.7 M | 85.1 M | 83.9 M | 82.3 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | 18.9 M | 18.9 M | 18.9 M | 18.9 M | 8.91 M | 8.91 M | 8.91 M | 8.91 M | 5.12 M | 5.12 M | 5.12 M | 5.12 M | 7.03 M | 7.03 M | 7.03 M | 7.03 M | 8.21 M | 8.21 M | 8.21 M | 8.21 M | 3.45 M | 3.45 M | 3.45 M | 3.45 M | 1.12 M | 1.12 M | 1.12 M | 1.12 M | 284 K | 284 K | 284 K | 284 K | 959 K | 959 K | 959 K | 959 K |
Book Value |
122 M | 119 M | 116 M | 117 M | 114 M | 121 M | 123 M | 127 M | 116 M | 116 M | 124 M | 126 M | 130 M | 141 M | 131 M | 131 M | 127 M | 125 M | 122 M | 50 M | 50 M | 50 M | 50 M | 44.9 M | 44.9 M | 44.9 M | 44.9 M | 18.5 M | 18.5 M | 18.5 M | 18.5 M | 6.22 M | 9.76 M | 9.76 M | 9.76 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 7.03 M | 7.03 M | 7.03 M | 7.03 M | 3.95 M | 4.01 M | 4.01 M | 4.01 M | 2.18 M | 2.18 M | 2.18 M | 2.18 M | 1.59 M | 2.15 M | 1.03 M | 2.89 M |
Total Shareholders Equity |
122 M | 119 M | 116 M | 117 M | 114 M | 121 M | 123 M | 127 M | 116 M | 116 M | 124 M | 126 M | 130 M | 141 M | 131 M | 131 M | 127 M | 125 M | 122 M | 50 M | 50 M | 50 M | 50 M | 44.9 M | 44.9 M | 44.9 M | 44.9 M | 18.5 M | 18.5 M | 18.5 M | 18.5 M | 6.22 M | 6.22 M | 6.22 M | 6.22 M | 7.81 M | 7.81 M | 7.81 M | 7.81 M | 8.94 M | 8.94 M | 8.94 M | 8.94 M | 4.61 M | 4.61 M | 4.61 M | 4.61 M | 1.67 M | 2.04 M | 2.04 M | 2.04 M | 1.4 M | 1.5 M | 1.5 M | 1.5 M | 1.59 M | 1.59 M | 1.59 M | 1.59 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of OptimizeRx Corporation, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Health information services
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B |  USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Premier
PINC
|
$ 28.26 | - | $ 2.33 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
Evolent Health
EVH
|
$ 4.0 | -1.23 % | $ 375 M | USA |
 |
Health Catalyst
HCAT
|
$ 2.39 | 0.42 % | $ 144 M | USA |
 |
HealthStream
HSTM
|
$ 23.07 | -0.86 % | $ 701 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
10x Genomics
TXG
|
$ 16.31 | 0.12 % | $ 1.91 B | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
HealthEquity
HQY
|
$ 91.61 | -0.96 % | $ 7.84 B | USA |
 |
Progyny
PGNY
|
$ 25.68 | -0.62 % | $ 2.2 B | USA |
 |
American Well Corporation
AMWL
|
$ 4.91 | 2.29 % | $ 73.6 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
So-Young International
SY
|
$ 2.56 | 1.59 % | $ 203 M |  China |
 |
Zhongchao
ZCMD
|
$ 0.45 | -26.63 % | $ 2.34 M | China |
 |
GoodRx Holdings
GDRX
|
$ 2.71 | 0.74 % | $ 1.05 B | USA |
 |
Omnicell
OMCL
|
$ 45.3 | -1.35 % | $ 2.09 B | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
Phreesia
PHR
|
$ 16.92 | -0.65 % | $ 923 M | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
Schrödinger
SDGR
|
$ 17.88 | 0.45 % | $ 1.3 B | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
Teladoc Health
TDOC
|
$ 7.0 | - | $ 1.19 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
Veeva Systems
VEEV
|
$ 223.23 | -0.63 % | $ 35.8 B | USA |
 |
SCWorx Corp.
WORX
|
$ 0.19 | -5.66 % | $ 277 K | USA |